Department of Health and Human Services (HHS) Secretary Xavier Becerra testified on May 12 before the House Energy and Commerce Health Subcommittee on President Joe Biden’s fiscal year (FY) 2022 HHS discretionary budget request, which proposes $131.7 billion in funding, an increase of $25 billion over FY 2021 [refer to
Throughout the hearing, subcommittee members raised a number of issues in their questions and comments, including the COVID-19 response and preparing for future public health crises, caring for unaccompanied children at the southern border, medical research, access to affordable health coverage, health equity, the 340B Drug Pricing Program, prescription drug pricing, maternal mortality, the opioid epidemic, telehealth coverage, and the Provider Relief Fund.
To embed, copy and paste the code into your website or blog:
Welcome to the first issue of the Latham & Watkins Drug Pricing Digest. Here, Latham’s government price reporting team provides a digest of recent developments, as reported in the trade press or published directly by government bodies, which we intend to distribute at the start of every second week. In this digest, we cover general developments, followed by sections focusing on the Medicaid Drug Rebate Program, the 340B Drug Pricing Program, Medicare Part B, and state law developments.
Please see full Publication below for more information.
Latham & Watkins May 10, 2021 | Number 1 | Page 1 May 10, 2021 | Number 1 Welcome to the first issue of the Latham & Watkins Drug Pricing Digest. Here, Latham’s government price reporting team provides a digest of recent developments, as reported in the trade press or published directly by government bodies, which we intend to distribute at the start of every second week. I